The skeletal dysplasias are a heterogeneous group of disorders which result in disproportionate short stature and/or skeletal deformities. This Program Project is directed toward a multidisciplinary investigation into the clinical, genetic, morphologic, biochemical and molecular characteristics of skeletal dysplasias.
The specific aims of this proposal are: (1) Expansion of the International Skeletal Dysplasia Registry. (2) Definition of the clinical and radiographic variability and genetic heterogeneity of the skeletal dysplasias and elucidation of the natural history, growth characteristics and complications of each of these disorders. (3) Improvement of methods for their prenatal diagnosis. (4) Elucidation of the histological, histochemical, immunohistological and ultrastructural characteristics of chondroosseous tissue in each of the skeletal dysplasias. (5) Identification of the disease genes in osteochondrodysplasias of unknown etiology. (6) Utilization of our human fetal cartilage cDNA library to find novel cartilage-specific cDNA clones. (7) Correlation of the clinical, radiographic and morphological features of each skeletal dysplasia with their specific biochemical and molecular defects. (8) Creation of a new mouse mutagenesis core to generate mouse models carrying null mutants or """"""""knock-in"""""""" mutants for each project within the Program Project (9) Definition of how mutations in genes encoding matrix proteins manifest at the molecular level in defective cartilage tissue in osteochondrodysplasias, (10) Elucidation of the role of the Wnt/Lmx1b/sFrp2 pathway in joint formation using mouse models. (11) Elucidation of the pathogenetic mechanism through which each of the mutations identified in man and mouse result in the specific skeletal dysplasia phenotype. This Program Project is divided into two core facilities, the International Skeletal Dysplasia Registry and a Mouse Mutagenesis Core, plus four separate grant proposals: (1) Clinical, morphological and molecular studies; (2) Matrix biochemistry in the skeletal dysplasias; (3) Molecular studies in the skeletal dysplasias; and (4) Developmental studies in the skeletal dysplasias.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
2P01HD022657-16
Application #
6361782
Study Section
Special Emphasis Panel (ZHD1-MCHG-B (RD))
Program Officer
Javois, Lorette Claire
Project Start
1986-12-01
Project End
2006-11-30
Budget Start
2002-05-28
Budget End
2002-11-30
Support Year
16
Fiscal Year
2002
Total Cost
$1,163,306
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Joeng, Kyu Sang; Lee, Yi-Chien; Lim, Joohyun et al. (2017) Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis. J Clin Invest 127:2678-2688
Madan, Simran; Liu, Wei; Lu, James T et al. (2017) A non-mosaic PORCN mutation in a male with severe congenital anomalies overlapping focal dermal hypoplasia. Mol Genet Metab Rep 12:57-61
Rajagopal, Abbhirami; Homan, Erica P; Joeng, Kyu Sang et al. (2016) Restoration of the serum level of SERPINF1 does not correct the bone phenotype in Serpinf1 null mice. Mol Genet Metab 117:378-82
Xue, Yuan; Schoser, Benedikt; Rao, Aliz R et al. (2016) Exome Sequencing Identified a Splice Site Mutation in FHL1 that Causes Uruguay Syndrome, an X-Linked Disorder With Skeletal Muscle Hypertrophy and Premature Cardiac Death. Circ Cardiovasc Genet 9:130-5
Lietman, Caressa D; Marom, Ronit; Munivez, Elda et al. (2015) A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation. J Bone Miner Res 30:489-98
Hudson, David M; Joeng, Kyu Sang; Werther, Rachel et al. (2015) Post-translationally abnormal collagens of prolyl 3-hydroxylase-2 null mice offer a pathobiological mechanism for the high myopia linked to human LEPREL1 mutations. J Biol Chem 290:8613-22
Chen, Shan; Grover, Monica; Sibai, Tarek et al. (2015) Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton. Mol Genet Metab 115:53-60
Homan, Erica P; Lietman, Caressa; Grafe, Ingo et al. (2014) Differential effects of collagen prolyl 3-hydroxylation on skeletal tissues. PLoS Genet 10:e1004121
Leddy, Holly A; McNulty, Amy L; Lee, Suk Hee et al. (2014) Follistatin in chondrocytes: the link between TRPV4 channelopathies and skeletal malformations. FASEB J 28:2525-37
Chen, Shan; Lee, Brendan H; Bae, Yangjin (2014) Notch signaling in skeletal stem cells. Calcif Tissue Int 94:68-77

Showing the most recent 10 out of 365 publications